Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques

Andreas Mörner, Marianne Jansson, Evelien M. Bunnik, Jørgen Schøller, Robert Vaughan, Yufei Wang, David C. Montefiori, Nel Otting, Ronald Bontrop, Lesley A. Bergmeier, Mahavir Singh, Richard T. Wyatt, Hanneke Schuitemaker, Gunnel Biberfeld, Rigmor Thorstensson and Thomas Lehner


Updated information and services can be found at:
http://jvi.asm.org/content/85/13/6442

These include:
Supplemental material

This article cites 46 articles, 11 of which can be accessed free at:
http://jvi.asm.org/content/85/13/6442#ref-list-1

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»
Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques

Andreas Mörner, Marianne Jansson, Evelien M. Bunnik, Jørgen Scholler, Robert Vaughan, Yufei Wang, David C. Montefiori, Nel Otting, Ronald Bontrop, Lesley A. Bergmeier, Mahavir Singh, Richard T. Wyatt, Hanneke Schuitemaker, Gunnel Biberfeld, and Thomas Lehner

Vaccinology Unit, Swedish Institute for Communicable Disease Control, Solna, Sweden; Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden; Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands; Immudex, Copenhagen, Denmark; Department of Tissue Typing, Kings College London, Guy’s Hospital, London, United Kingdom; Mucosal Immunology Unit, Kings College London, Guy’s Hospital, London, United Kingdom; Department of Immunology, Duke University Medical Center, Durham, North Carolina; Department of Comparative Genetics and Refinement, Biomedical Primate Research Centre, Rijswijk, Netherlands; Queen Mary, University of London, Barts and The London Schools of Medicine and Dentistry, Centre for Clinical and Diagnostic Oral Sciences, London, United Kingdom; Lionex GmbH, Braunschweig, Germany; and Vaccine Research Center, NIH, Bethesda, Maryland

Received 19 January 2011/Accepted 4 April 2011

Major histocompatibility complex (MHC) molecules expressed on the surface of human immunodeficiency virus (HIV) are potential targets for neutralizing antibodies. Since MHC molecules are polymorphic, nonself MHC can also be immunogenic. We have used combinations of novel recombinant HLA class I and II and HIV/simian immunodeficiency virus (SIV) antigens, all linked to dextran, to investigate whether they can elicit protective immune responses against heterologous simian/human immunodeficiency virus (SHIV) challenge in rhesus macaques. Three groups of animals were immunized with HLA (group 1, n = 8), trimeric YU2 HIV type 1 (HIV-1) gp140 and SIV p27 (HIV/SIV antigens; group 2, n = 8), or HLA plus HIV/SIV antigens (group 3, n = 8), all with Hsp70 and TiterMax Gold adjuvant. Another group (group 4, n = 6) received the same vaccine as group 3 without TiterMax Gold. Two of eight macaques in group 3 were completely protected against intravenous challenge with 18% 50% animal infective doses (AID50) of SHIV-SF162P4/C grown in humans expressing HLA class I and II lineages represented in the vaccine, while the remaining six macaques showed decreased viral loads compared to those in unimmunized animals. Complement-dependent neutralizing activity in serum and high levels of anti-HLA antibodies were elicited in groups 1 and 3, and both were inversely correlated with the plasma viral load at 2 weeks postchallenge. Antibody-mediated protection was strongly supported by the fact that transfer of pooled serum from the two challenged but uninfected animals protected two naïve animals against repeated low-dose challenge with the same SHIV stock. This study demonstrates that immunization with recombinant HLA in combination with HIV-1 antigens might be developed into an alternative strategy for a future AIDS vaccine.

The need for a prophylactic human immunodeficiency virus (HIV) vaccine remains urgent, especially in the developing world. It is widely believed that an effective vaccine against HIV/AIDS will have to induce responses of both the cellular and humoral arms of the immune system. However, despite many years of intense research, attempts to elicit potent and broadly neutralizing antibodies against HIV have so far been unsuccessful. This is largely due to the enormous diversity of the HIV-encoded targets for neutralizing antibodies, i.e., the surface and transmembrane Env glycoproteins, gp120 and gp41, respectively, which enables virus variants to escape antibody recognition. In addition, these viral glycoproteins have other mechanisms to protect themselves from neutralizing antibodies, such as shedding of gp120, glycan shielding, and masking of conserved structures (reviewed in reference 14). Alternative strategies for inducing effective humoral immune responses against HIV are therefore desirable.

When a nascent HIV virus particle buds from an infected cell, it incorporates several host cell proteins into its envelope membrane. Among these proteins are the major histocompatibility complex (MHC) class I and II molecules (reviewed in reference 25). It has been repeatedly shown that xenoinmunization of macaques, with either human cells alone, purified human leukocyte antigen (HLA) class I or class II proteins, or, more efficiently, fixed simian immunodeficiency virus (SIV)-
infected human cells or inactivated SIV grown in human cells can provide sterilizing immunity against subsequent challenge with SIV (1, 5, 16, 31, 39). Anti-HLA antibodies are likely to be involved in this protection, by direct neutralization, complement-dependent inhibition, or some other mechanism (5), but cellular and/or innate immune responses may also play a role (45).

The HLA molecules are the most polymorphic human proteins, and as nearly every individual has a unique suite of HLA antigens, exposure to foreign HLA can result in an alloimmune response against the variable regions of the HLA molecules. Thus, the mechanism of protection against SIV by xenoinmunization may also be effective in alloimmunization against HIV. So far this possibility has not been extensively studied, but several observations support the concept. Whole-cell alloimmunization of women with their partner’s leukocytes elicited resistance to HIV replication in vitro (46), and their sera neutralized HIV grown in their partner’s peripheral blood mononuclear cells (PBMC) (18). There were no adverse effects, and since similar alloimmunization procedures have been carried out with over 1,000 women, this practice appears to be safe. Patients receiving multiple blood transfusions also develop alloresponses, including anti-HLA antibodies, and these antibodies neutralized HIV grown in cells expressing the corresponding HLA lineages (35). Furthermore, the observation that mother-child HLA class I concordance (20) is associated with an increased perinatal HIV type 1 (HIV-1) transmission rate suggests that allogeneic immune responses may have a protective effect. In a clinical trial with a fixed inactivated HIV-1 vaccine, participants developed anti-HLA antibody responses concordant with the host cell line used for vaccine production, showing the potential for alloimmunization (29). In a potential future prophylactic allovaccine against HIV, a sufficient number of different HLA lineages would have to be included to elicit immune responses, and thereby protection, in >90% of the population. In, e.g., a sub-Saharan population, four HLA class I alleles (HLA-A*01:01, -A*02:01, -A*03:01, and -A*29:01) would be sufficient to obtain such HLA coverage (unpublished data).

To explore xenovaccination as an alternative strategy for eliciting protective immunity against SHIV challenge in a proof-of-concept study, we immunized macaques with recombinant HLA class I and II molecules, with or without trimeric HIV-1 gp140 and SIV p27 proteins and the TiterMax Gold adjuvant, and challenged them intravenously with functional peptide-MHC complexes. The HLA-immunized macaques displayed complement-dependent neutralization activity in serum and anti-HLA antibodies that correlated inversely with the viral load at 2 weeks after challenge.

MATERIALS AND METHODS

Vaccine preparation. Four HLA class I alleles and one HLA class II allele were selected, as they are common in the Caucasian population (8), their peptide folding is known, and they are likely to stimulate an alloantibody response in the majority of humans (shown together with their respective folding peptide in parentheses): (i) HLA-A*01:01 (IVDCLTEMY), (ii) HLA-A*02:01 (GLIQLVE GV), (iii) HLA-A*03:01 (RIAAWMATY), (iv) HLA-A*11:01 (VTD5F5VIK), and (v) HLA-DRB1*04:01. Preparation of recombinant HLA class I heavy chains and β2 microglobulin (β2 M) was described in detail elsewhere (32). Briefly, synthetic genes encoding the protein-coding sequence minus the signal peptide and transmembrane regions of the human MHC class I alleles were created by PCR of overlapping DNA primers based on GenBank sequence information. Recombinant HLA class I and β2 M were produced by fermentation, isolated, and purified. The HLA heavy chain was biotinylated before folding together with β2 M and peptide into functional peptide-MHC complexes. HLA-DRB1*04:01 was purchased from Bethane Research Institute, Seattle, WA. Briefly, HLA-DRB1*04:01-leucine zipper-biotinylation site expression vectors made using the PCR-mediated splicing overlap technique together with the plasmid pUCHneo, which carries the neomycin resistance marker, were cotransfected into Schneider cells S-2 by standard calcium phosphate transfection techniques. The DRB1*04:01 molecules were purified by affinity chromatography using L243 as described previously (36), biotinylated, and then loaded with peptide by incubation for 72 h at 37°C.

The Yu2 HIV-1 gp140-foldon trimers were genetically engineered by PCR-mediated cloning to encode a C-terminal, site-specific biotinylation motif known as an AviTag sequence (GeneCopoeia, Rockville, MD). The C terminus of the gp140 trimeric glycoproteins thereby ended with the HIV-1-encoded gp41 sequence at residue 683 K (HXB2 numbering), following the foldon motif (as previously described [47]), followed by a His6 purification tag and finally the AviTag sequence. The recombinant proteins were expressed in Freestyle 293F cells, purified, and concentrated, and the trimeric fraction was isolated as previously described (23). Following purification, the trimers were monobiotinylated using biotin and biotin ligase as per the manufacturer’s instructions (GeneCopoeia).

Monobiotinylated SIV p27 was produced following subcloning and excision of the glutathione S-transferase (GST) fusion partner from the original clone (SIV p27GST) (21). The C-terminal fragment of Mycobacterium tuberculosis Hsp70 (positions 359 to 609) (2) was subcloned to enable in vitro biotinylation. A primer of 76 bases for PCR that allowed fusion of the recognition site for in vivo biotinylation in Escherichia coli to the C-terminal ends of SIV p27 and Hsp70p27 was designed. The proteins were expressed and purified from recombinant BL21 (DE3). To achieve a higher purity, the protein(s) underwent two further purification steps by anion-exchange and size exclusion chromatography.

For preparation of the dextramer vaccine complexes, the biotinylated peptide-MHC class I and class II complexes, trimeric HIVgp140, SIVp27, and Hsp70p27 were linked to a streptavidin-coated, divinyl sulfone acid-actidextran backbone (32).

Animals and immunizations. The study was carried out in compliance with the provisions and general guidelines of the Swedish Animal Welfare Agency, and all procedures were approved by the Ethical Committee on Animal Experiments of North Stockholm (permit number N90/06). Thirty-eight female rhesus macaques (Macaca mulatta) of Chinese origin, 3 to 5 years old at the start of the study, were housed in the Astrid Fagraeus laboratory at the Swedish Institute for Communicable Disease Control. Immunizations and blood sampling were performed under sedation with ketamine at 10 mg/kg intramuscularly (i.m.) (Ketaminol, 100 mg/ml, Intervet, Sweden). Before entering the study, all animals were confirmed to be negative for simian immunodeficiency virus (SIV), simian T-cell lymphotropic virus, and simian retrovirus type D. The MHC class I alleles were determined for all animals. RNA isolation, reverse transcription-PCR (RT-PCR), and cloning and sequencing of macaque class I A and B alleles were described elsewhere (26, 27). Unreported alleles, of which at least three full-length clones were present, were submitted to the EMBL-EBI database and also to the non-human primate MHC section of the Immuno Polymorphism Database (for official designations, see reference 26).

Groups of eight animals were immunized with HLA class I (A*01:01, A*02:01, A*03:01, and A*11:01; 100 μg of each/full dose) and class II (DRB1*04:01; 113.5 μg/full dose) (group 1), trimeric Yu2 HIV-1 gp140 and SIV Gag p27 (HIV/SIV antigens; 152.4 and 37.1 μg/ml, respectively) (group 2), or both (group 3), all together with Hsp70p27 (3 × 12.5 μg/ml, full dose) and coupled to dextran backbones (162.2 to 648.8 μg/ml, full dose, depending on the number of attached components). Group 1 to 3 animals received a full vaccine dose at the first immunization and half doses at the subsequent immunizations. The vaccines for groups 1 to 3 were given subcutaneously (s.c.) formulated as an emulsion with the TiterMax Gold adjuvant (0.5 ml/full dose; Sigma-Aldrich, St. Louis, MO). Six additional animals (group 4) received the same vaccine as group 3 but without TiterMax Gold, i.m., and with full vaccine doses at all immunizations. Group 5 control animals were unvaccinated (Table 1).
TABLE 1. Immunizations and challenge*  

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Dextramer immunogens</th>
<th>Adjutant</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>8</td>
<td>HLA-I/II + Hsp70 + dextran</td>
<td>TierMax Gold</td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>HIV-1 gp140/SIV p27 + Hsp70 + dextran</td>
<td>TierMax Gold</td>
</tr>
<tr>
<td>3</td>
<td>8</td>
<td>HLA-I/II + HIV-1 gp140/SIV p27 + Hsp70 + dextran</td>
<td>TierMax Gold</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>HLA-I/II + HIV-1 gp140/SIV p27 + None</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

* The animals in groups 1 to 4 were immunized four times, at weeks 0, 4, 8, and 16. Four weeks after the last immunization, all vaccinated animals plus eight naïve animals (group 5) were challenged i.v. with 18 AIDSO of SHIV-SF162P4/C. For details, see Materials and Methods.
by centrifugation and the depleted serum was harvested; >95% of the C8166 and C8166-CCR5 binding IgG was removed from the serum pool.

**Viron lysis assay.** Sera from immunized rhesus macaques immunized with HLA antigen were obtained at the time of challenge and analyzed for the ability to induce complement-mediated lysis of the challenge virus. An aliquot of 200 μl of the SHIV-SF162P4/C stock diluted 1/10 in medium, corresponding to approximately 1 × 10⁴ virus copies or 4,500 TCID₅₀ (according to titration on C8166-CCR5 cells), 200 μl of rhesus serum diluted 1/10 or 1/50 in medium, and 10% of complement source (45 μl of human serum pooled from four donors) were mixed and incubated at 37°C for 1 h. Virus was incubated in parallel with normal rhesus serum, medium, or heat-inactivated (56°C, 60 min) complement source. Nonlysed virus was pelleted after incubation by high-speed centrifugation for 90 min at 8°C. Subsequently, the SHIV core antigen content in supernatant (i.e., lysed virus) was analyzed by Vironostika HIV-1 antigen ELISA (bioMérieux, Boxtel, Netherlands), which is cross-reactive for SIV antigens, according to the manufacturer’s instructions.

**Statistical analyses.** The nonparametric Mann-Whitney and Spearman tests were used, with Dunn’s correction for multiple tests where appropriate. GraphPad Prism software was used for statistical analysis.

**Nucleotide sequence accession numbers.** The sequences of the new alleles determined in this study have been submitted to the EMBL-EBI database and to the nonhuman primate MHSC section of the Immunovir Polymorphism Database under accession numbers FN985452 to FN985480 and FN995437.

**RESULTS**

**Protection against SHIV-SF162P4/C by immunization with recombinant HLA and HIV/SIV antigens.** To explore xenoinmunization as a strategy for eliciting protective immunity against SHIV challenge, four groups of macaques were immunized at weeks 0, 4, 8, and 16, as summarized in Table 1, with vaccine components couped to dextran backbones, forming so-called dextramers. Group 1 (n = 8) was immunized with HLA, group 2 (n = 8) with trimeric YU2 HIV-1 gp140 and SIV p27 (HIV/SIV antigens), and groups 3 (n = 8) and 4 (n = 6) with both HLA and HIV/SIV antigens. All groups also received Hsp70, and all groups except group 4 were given the TiterMax Gold adjuvant. Four weeks after the last immunization, all vaccinated animals plus eight naïve animals (group 5) were challenged with 18 AID₅₀ of SHIV-SF162P4/C. This virus stock was grown in C8166-CCR5 cells, a T-cell line expressing HLA-A*01 and -DRB1*04; both lineages are part of the HLA component of the vaccine. The virus particles should therefore express on their surface both HLA class I and class II lineages, A*01, B*08, or B*17 (reviewed in reference 2). Neutralizing activity in the presence of complement by sera from group 4 animals was significantly shorter than that for the unvaccinated animals (2 compared with 3 weeks, respectively; P < 0.01). Mamu typing revealed that none of the reported protective Mamu class I lineages, A*01, B*08, or B*17 (reviewed in reference 13), was present in any animal.

In summary, protection from infection or control of viral replication was achieved in animals that had been immunized with both HLA and HIV/SIV antigens and the TiterMax Gold adjuvant.

**SHIV-neutralizing activity in serum.** In order to study correlates of vaccine-induced protective immunity, macaque sera obtained at time points before, during, and after immunization were tested for their relative in vitro neutralizing activities against the challenge virus SHIV-SF162P4/C. The neutralizing activities of macaque sera were analyzed in both the absence and presence of complement. Indeed, in sera from group 1 and group 3 macaques, both of which were immunized with HLA, neutralizing activity was observed only in the presence of complement (Fig. 2A). In contrast, sera from group 2 animals, immunized with HIV/SIV antigens but not HLA, yielded significant neutralizing activity with and without complement, but the former was at a reduced level compared with groups 1 and 3. Neutralizing activity in serum became detectable after the second immunization and was enhanced in some but not all animals after the third and/or fourth immunization (see Fig. S1A in the supplemental material). No inhibition of a VSV-G-pseudotyped HIV variant by group 1 and group 3 sera in the presence of complement was observed (data not shown), suggesting that the observed neutralizing activity in group 1 and 3 sera was not the result of an effect of these sera on the viability of the target cells in the neutralization assay. Furthermore, neutralizing activity of sera from 5/8 group 2 animals was inhibited in the presence of a peptide representing the BaL V3 region (see Fig. S1B in the supplemental material), confirming that the activity in these sera was directed against the virally encoded envelope glycoproteins. In contrast, the neutralizing activity in sera from group 3 animals was not reduced in the presence of BaL V3 peptide. Neutralization in the presence of complement by sera from group 4 animals was only slightly enhanced compared to that by sera from the control animals (Fig. 2A), suggesting that the TiterMax Gold adjuvant was essential for the development of a potent neutralizing activity. There was an inverse correlation between neutralizing activity in the presence of complement and plasma viral load at 2 weeks postchallenge in the immunized macaques (r = −0.43; P = 0.018) (Fig. 2B).

**Antibodies directed against HLA classes I and II and the C8166-CCR5 cell line.** High antibody levels, detectable at a 1/1,000 dilution, were elicited in groups 1 and 3 to all four HLA class I recombinant antigens and one class II recombinant antigen of the vaccine, whereas in group 4 only weak anti-HLA...
antibody responses were detected (Fig. 3A and B). HLA binding antibodies were absent in all preimmunization sera and were not detected in group 2 (not immunized with HLA antigens) or in the unimmunized group 5 animals.

In the HLA-immunized macaques in groups 1 and 3 (both of which received the TiterMax Gold adjuvant), there was a correlation between the level of antibodies against HLA-A*01 and HLA-DRB1*04, the two immunizing HLA lineages expressed on the surface of the challenge virus, and serum neutralizing activity in the presence ($r = 0.57; P = 0.02$) (Fig. 3C), but not in the absence ($r = -0.02; P = 0.95$), of complement. Moreover, anti-A*01 and -DRB1*04 antibodies also correlated inversely with the viral load at 2 weeks postchallenge ($r = -0.57; P = 0.005$) in the immunized animals, as did anti-A*01 ($r = -0.51; P = 0.016$) but not anti-DRB1*04 ($r = -0.36; P = 0.099$) antibodies (data not shown).

Measuring antibodies against the C8166-CCR5 cell line provided a method for detection of antibodies recognizing the challenge virus-matched HLA molecules in their native conformation. High levels of anti-C8166-CCR5 IgG antibodies were elicited in groups 1 and 3, while only weak responses were seen in group 4 (Fig. S2 in the supplemental material). At the time of challenge, anti-C8166-CCR5 antibody responses within groups 1 and 3 correlated with the cumulative anti-A*01 and -DRB1*04 antibody responses as measured by Luminex ($r = 0.56; P = 0.023$), both lineages expressed by C8166-CCR5. Furthermore, in these macaques the anti-C8166-CCR5 antibody levels correlated strongly with neutralization in the presence ($r = 0.68; P = 0.0036$) but not in the absence ($r = -0.44; P = 0.086$) of complement (Fig. 4B).

Anti-gp120 antibodies. Vaccine-induced anti-gp120 antibodies were elicited in all animals in groups 2, 3, and 4 (see Fig. S2 in the supplemental material), with median titers reaching plateau levels after the second immunization (Fig. 5A). The highest titers at the time of challenge were detected in group 2, immunized with HIV/SIV antigens plus TiterMax Gold, with a median titer of 13,889, which was significantly higher than those in group 3 (5,042) and 4 (3,048) ($P < 0.05$ and $P < 0.001$,
respectively) (Fig. 5B). Within groups 2 and 3, both of which received HIV/SIV antigens together with TiterMax Gold, anti-gp120 antibodies correlated strongly with neutralization in the absence \((r = 0.82; P < 0.0001)\) but not in the presence \((r = -0.30; P = 0.26)\) of complement (Fig. 5C). There was no correlation between the anti-gp120 antibody levels at the time of challenge and plasma viral load. All macaques in groups 2, 3, and 4 showed anamnestic anti-gp120 antibody responses at 4 weeks after challenge, except the protected macaques F42 and F44 (see Fig. S2 in the supplemental material).

**Env- and Gag-specific T-cell responses.** Since Env and Gag proteins were included in the vaccines given to groups 2, 3, and 4 we tested the T-cell responses against these proteins to see if they were contributing to the control of virus replication. Simultaneous measurement of IFN-\(\gamma\) and IL-2 secretion after stimulation with vaccine-homologous HIV Env or SIV Gag overlapping peptide pools was carried out using the novel Fluorospot assay. Frozen PBMC from the time of challenge and 1 week after challenge were tested. Substantial anti-Env and -Gag responses were observed in groups 2 and 3, while responses in group 4 were weak or absent (see Fig. S3 in the supplemental material). However, we found no correlation between the T-cell responses and viral load.

**Protection against SHIV infection by passive immunization.** To investigate whether the complete protection observed in F42 and F44 was mediated by antibodies, a passive immunization experiment was performed. After being given two additional booster immunizations, these two animals were sacrificed and serum was collected. Pooled and heat-inactivated serum (36 ml/kg of body weight) was administered i.p. to two naïve animals, F101 and F102. Since only 2/8 animals were protected against infection in group 3, we reasoned that the challenge virus dose might have been too high to reveal the full protective potential of the vaccine. As we were also uncertain whether binding/neutralizing serum antibody titers of the same magnitude would be reached in the passively immunized animals, we decided to challenge the macaques repeatedly with a lower virus dose. F101 and F102 as well as two control animals,
which received normal rhesus serum, were therefore challenged i.v. with 0.6 AID$_{50}$ of SHIV-SF162P4/C twice weekly for 3 weeks, starting 24 h after the serum transfer (day 1).

The anti-C8166-CCR5 IgG MFI in the immune serum pool was 21,151, and at day 1 the serum titers in F101 and F102 were 6,951 and 5,742, respectively (see Fig. S4A in the supplemental material). At the time of the last virus challenge, day 20, the titers had decreased to 2,668 and 2,292, respectively (half-life $t_{1/2}$, 14.0 and 14.1 days, respectively). For comparison, the serum antibody titers to C8166-CCR5 of F42 and F44 at the time of challenge in the original experiment were 4,443 and 11,971, respectively. The neutralizing activities against the challenge virus 1 day after the serum transfer were 388 and 455 ID$_{50}$ in F101 and F102, respectively, and by the time of the last challenge they had decreased to 97 and 136 ID$_{50}$, respectively (see Fig. S4B in the supplemental material). The two control macaques, F118 and F119, became viremic at day 20, with peak viremias of 6.6 and 6.1 log$_{10}$ RNA eq/ml plasma reached at days 27 and 34, respectively (Fig. 6). In contrast, F101 and F102 remained nonviremic until they were sacrificed at day 77, showing that the protection seen in group 3 could be transferred by passive immunization with serum. None of the reported protective Mamu class I lineages (A*01, B*08, or B*17) was present in these four animals.

**Specificity and mechanism of complement-dependent neutralization.** To determine the specificity of the complement-dependent neutralization, sera from F42 and F44 taken at 2 weeks after the fifth immunization were pooled and mixed with C8166 cells in order to deplete antibodies specific for cell surface molecules present on these cells. By this method $>95\%$ of both C8166 and C8166-CCR5 binding antibodies were depleted. When tested for neutralization in the presence of complement, all neutralizing activity was found to be lost in the depleted sera (Table 2).

In order to elucidate whether the complement-dependent neutralizing activity mediated by anti-HLA antibodies could be linked to lysis of virions, a virion lysis assay was set up. The challenge virus, SHIV-SF162P4/C, was incubated with sera obtained after HLA immunization, at the time of challenge, from group 1 animals displaying the strongest complement-dependent neutralizing activity (F14 and F31). Indeed, sera from these animals lysed the challenge virus in a dose-dependent fashion in the presence of active complement (Fig. 7); at the lowest serum dilution tested (1/20), 56 and 39\% were lysed.

![FIG. 3. Serum anti-HLA IgG levels in immunized animals (groups 1, 2, 3, and 4) at the time of challenge, measured by Luminex at a 1/1,000 dilution. The protected animals (F42 and F44) are denoted by empty symbols. (A) IgG antibodies directed against the vaccine HLA class I antigens. (B) IgG antibodies directed against the vaccine HLA class II antigen. (C) Correlation between anti-A*01 and -DRB1*04 IgG and neutralizing antibodies, in the presence of complement, in groups 1 and 3.](http://jvi.asm.org/)
respectively, while using inactivated complement resulted in only 6 and 5% lysis, respectively. Normal rhesus serum or medium did not induce any substantial amount of virion lysis in the presence of active complement. Taken together, these results suggest that virion lysis contributes significantly to complement-dependent neutralizing activity in sera from macaques immunized with HLA.

**DISCUSSION**

In this study we present evidence that immunization with a combination of recombinant HLA class I and II proteins and HIV/SIV antigens (Env and Gag proteins) can protect macaques against i.v. challenge with heterologous SHIV. The protection was complete in two of eight macaques and resulted in decreased viral loads in the remaining six immunized macaques. A passive immunization experiment revealed that the protective immunity could be transferred to naïve animals using immune serum from the two protected animals.

Using, for the first time, recombinant HLA proteins and thereby eliminating the potential risk of incompletely inactivated viruses or transmission of other cell-associated viruses, this investigation confirms and extends previous studies where protection against SIV grown in human cells was achieved by immunization with fixed SIV-infected human cells or with inactivated SIV grown in human cells (16, 31, 41). However, whereas protection after immunization with uninfected human cells (39), mouse cells expressing HLA class II (40), or purified HLA class I or II proteins (1, 5) has been reported, we did not observe any protection after recombinant HLA immunization in the absence of HIV/SIV antigens (Env and Gag). The reason for this is not clear, but the observation is in line with previous studies which revealed that immunization with fixed SIV-infected human cells or inactivated SIV grown in human cells gave greater and more consistent protection (16) than immunization with uninfected human cells, although the latter studies are few and included small numbers of animals (39).

The protection elicited by transfer of immune serum confirms previous observations (40) and for the first time demonstrates that protection against heterologous SHIV challenge can be achieved by passive immunization with sera from animals immunized with HLA molecules in combination with HIV/SIV antigens in the absence of other cell components. This offers further evidence that antibodies mediated the protection. Indeed, potent complement-dependent neutralizing activity was observed in sera from the protected group 3 macaques, which were immunized with all components, and it correlated inversely with viral load at 2 weeks postchallenge.

As protection was achieved in macaques that were immunized with both HLA class I and II and HIV/SIV antigens...

FIG. 4. Serum anti-C8166-CCR5 IgG in immunized animals that received HLA-containing vaccine (groups 1, 3, and 4). Anti-C8166-CCR5 IgG was detected by FITC-conjugated anti-human IgG secondary antibody, and the mean fluorescence intensity (MFI) was measured. (A) Anti-C8166-CCR5 at the time of challenge. (B) Correlation between anti-C8166-CCR5 IgG and neutralizing antibodies, in the presence of complement, in groups 1 and 3. The protected animals F42 and F44 are denoted with empty symbols.

FIG. 5. Serum anti-gp120 IgG in immunized animals that received HIV/SIV antigen-containing vaccine (groups 2, 3, and 4). (A) Median endpoint titers over time. The dashed line indicates the time of challenge. (B) Individual endpoint titers at the time of challenge. (C) Correlation between anti-gp120 IgG levels (log_{10} titer) and neutralizing activity in the absence of complement (ID_{50}) at the time of challenge in groups 2 and 3. The protected animals (F42 and F44) are denoted with empty symbols.
in those studies other polymorphic cell surface molecules, such as ICAM-1 or LFA-1, could not be ruled out as targets for complement-dependent neutralization, here the only cell membrane molecules used for immunization were HLA class I and II. It is also noteworthy that the anti-gp120 antibody levels in groups 2 and 3, the two groups immunized with Env proteins and TiterMax Gold adjuvant, correlated with neutralization in the absence of complement, suggesting that the anti-Env antibodies mediated complement-independent neutralization. The minimal neutralizing activity in the absence of complement and the lack of neutralization inhibition by Bal V3 peptide indicate that the immunization regime in group 3 animals has failed to elicit anti-Env antibodies with neutralizing capacity.

The mechanism of complement-mediated inhibition of HIV-1 infection could be either by virion lysis through antibody-mediated activation of the classical complement pathway (34) or by steric hindrance of viral entry as a consequence of dense coating of the virus particle with antibody plus complement (42). Other possible antibody-dependent complement-mediated antiviral mechanisms are phagocytosis (3) and regulation of adaptive immunity (4). Here we demonstrate that incubation of SHIV particles bearing HLA class I and II matching the vaccine with serum from HLA-immunized macaques and active complement caused more than 50% virion lysis at the lowest serum dilution tested. This suggests that a major part of the neutralizing activity in group 1 and 3 macaques was mediated by HLA-directed antibody-dependent complement-mediated virion lysis, and it is in agreement with studies on alloimmune human serum neutralization of HIV-1 (33, 35). We cannot, however, exclude the possibility that steric hindrance by antibody and complement coating of the virions may play a role.

We hypothesize that in the two completely protected macaques of group 3 and in the two passively immunized macaques, the challenge virus was blocked in the preentry phase of the infection, by anti-HLA antibodies or by a combination of anti-HLA and -Env antibodies. We postulate that in the remaining group 3 macaques, which became infected but displayed significantly lower levels of virus replication, the inoculated virus was incompletely neutralized, leaving a reduced virus inoculum, which delayed the replication of the virus and thereby allowed a better control by the virus-specific adaptive immunity. A trend toward delayed viremia in the macaques immunized with HLA only (group 1) was observed, and in preceding in vivo titrations of the challenge virus stock we observed an inverse correlation between the size of the virus inoculum and the time to peak viremia. There was, however, no delayed viremia in the HLA- and HIV/SIV antigen-immu-

<table>
<thead>
<tr>
<th>Serum</th>
<th>Without complement</th>
<th>With complement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nonadsorbed</td>
<td>&lt;40</td>
<td>&gt;1,280</td>
</tr>
<tr>
<td>C8166 adsorbed</td>
<td>&lt;40</td>
<td>&lt;40</td>
</tr>
</tbody>
</table>

*Pooled sera from animals F42 and F44 taken after the fifth immunization were preadsorbed with C8166 cells and then tested for neutralizing activity against SHIV-SF162P4/C in the absence or presence of complement. For details, see Materials and Methods.

FIG. 6. Plasma viral load in passively immunized macaques after repeated i.v. SHIV-SF162P4/C challenge. Immune sera from protected animals F42 and F44 were transferred to naïve animals F101 and F102, while control serum was given to F118 and F119. Starting the following day, all animals were challenged i.v. twice weekly for 3 weeks with 0.6 AID<sub>50</sub> of SHIV-SF162P4/C (dashed lines).
be speculated that the HIV/SIV antigen-specific cellular re-

FIG. 7. Anti-HLA antibody- and complement-mediated virion lysis. Lysis of SHIV-SF162P4/C virions in the presence of complement and immune sera from HLA immunized animals is shown. Sera from group 1 animals (F14 and F31), normal rhesus serum (NRS) or medium only (−) was incubated with SHIV-SF162P4/C in the presence (+) or absence (−) of complement. NA, not applicable.
nized group 3 animals. Since in the macaques immunized with HIV/SIV antigen only (group 2) the median peak viremia occurred significantly earlier than in the control animals, it may be that the forces driving and slowing the viral replication in groups 2 and 1, respectively, counteract each other in the HLA- and HIV/SIV antigen-immunized group 3 animals. The earlier peak viremia in group 2 animals was unexpected. It can be speculated that the HIV/SIV antigen-specific cellular responses provided an expanded pool of CD4+ target cells for the virus. Similar findings have been reported after vaccination against both SIV and feline immunodeficiency virus (FIV) (17, 36), and SHIV- and HIV-1-specific CD4+ T cells were shown to be preferentially infected in macaques and humans, respectively (9, 37).

As demonstrated above, immunization with HLA, especially in combination with viral antigens, can protect macaques against challenge with SIV or SHIV grown in human cells, i.e., protection by xenoinmunization. Together with observations in humans, indicating that alloimmune responses may confer protection against HIV (18, 20, 29, 35), this provides support for the hypothesis that this vaccination strategy could be transferred to humans and HIV. However, this would require alloimmunization with MHC class I and II antigens. To our knowledge, only two macaque studies testing alloimmunization against SIV infection have been published; one showed protection (40), and another failed to show protection (30). This discrepancy can be accounted for by a number of parameters such as differences in vaccine production, challenge dose, adjuvant, and route of immunization. Clearly, further studies are required.

The present study has used a multicomponent vaccine strategy, and further investigation is needed to identify the critical components for protection. It is clear that a strong adjuvant, such as TiterMax Gold, was an essential component of the vaccine, but we cannot from our results determine the necessity of including Hsp70 or linking the vaccine components with dextran. Mycobacterial Hsp70 binds to CD40 (43) and has been shown to possess adjuvant properties when fused or linked to an antigen (12, 19, 44). The C-terminal fragment (amino acids 359 to 609) was chosen for this study, as it has been shown to be essential for the adjuvant effect (19, 44). We were not able to compare immunizations with and without Hsp70, but its effect on the humoral and cellular immune responses appeared to be modest, especially compared to the additional effect of TiterMax Gold. Similarly, we need to determine whether both HIV-1 gp140 and SIV p27 are critical for protection. Besides the effect of anti-Env antibodies discussed above, it is possible that anti-Env and/or -Gag cellular responses may play a role in the increased control of viral replication in group 3 macaques, although no correlation between IFN-γ or IL-2 secretion and viral load was found in these animals. Neither can we conclude that both HLA class I and II are essential for protection. Previous reports are contradictory, perhaps because different cell lines with different HLA expression patterns have been used for immunization or for propagating virus for immunization and challenge. In our study anti-HLA class I antibodies correlated best with protection, and this is in agreement with other studies where the same cell line, C8166, has been used for propagation of the challenge virus (5, 6).

We have demonstrated that protection against i.v. challenge with heterologous SHIV in macaques can be achieved by immunization with a combination of recombinant HLA and HIV/SIV antigens. The protection appears to be mediated by antibodies, likely directed against HLA class I and HIV-1 Env. Further investigations are needed to establish which components are critical for protection and whether similar protection can be achieved by alloimmunization with MHC and against mucosal challenge.

ACKNOWLEDGMENTS

We thank L. Wehlin, E. Hansson-Pihlainen, L. Bergqvist, I. Silhorman, O. Shaw, T. Seidl, R. Spallek, C. Halgreen, and L. Brix for excellent technical assistance. We also thank veterinarian M. Spångberg and the staff at Astrid Fagreus laboratory for excellent animal care. We greatly appreciate N. Miller providing SHIV-SF162P4, the advice received from W. W. Kwok, and N. Ahlborg at Mabtech AB providing Fluorosorp material and reagents.

This study was funded by Bill & Melinda Gates Foundation grant 38608 as part of the Collaboration for AIDS Vaccine Discovery (CAVD). Development and production of trimERIC HIV-1 gp140 was supported by the NIH intramural research program.

REFERENCES


